Tillat Pharmaceuticals, Inc. manufactures and distributes high-demand medications to an array of countries including Lebanon, Indonesia, Saudi Arabia, Malaysia, and UAE, among others. It focuses on commercializing halal medications – those produced within the constraints of Islamic requirements and regulations – and seeks to provide access to halal-compliant medicines for all consumers globally. Tillat currently has a pipeline of 16 generic medications (8 biotherapeutics and 8 small molecules), at various stages of development, which provide halal-compliant alternatives to the leading therapies worldwide. The Company expects a majority of these medications to be available to consumers by the end of 2024. The company is headquartered in San Diego, California, and has regional offices in Beirut, Lebanon, and Rio De Janeiro, Brazil.